RNA

The 2024 Nobel Prize in Physiology or Medicine has been awarded to Victor Ambros '75, PhD '79 and Gary Ruvkun for the discovery of microRNA, “a tiny class of RNA molecules that play a crucial role in determining how organisms mature and function – and how they sometimes malfunction,” reports Teddy Rosenbluth and Derrick Bryson Taylor for The New York Times. Ambros and Ruvkun “had been postdoctoral fellows at the same time at Massachusetts Institute of Technology,” they explain . “As they studied C. elegans, they at first felt a smidgen of friendly competition as they each started their own labs in the Boston area, Dr. Ambros said.”

Victor Ambros '75, PhD '79 and Gary Ruvkun have won the 2024 Nobel Prize in Physiology or Medicine for the discovery of microRNAs, report Mark Johnson and Lizette Ortega for The Washington Post. “Ambros and Ruvkunhad worked together as postdoctoral researchers in the lab of Nobel laureate and MIT Professor Robert Horvitz. “What the microRNAs really end up revealing for us is a way that parts of our genome can communicate with other parts of the genome,” says Ambros. “The significance of this discovery of microRNAs is that it allowed us to be aware of a very complex and nuanced layer of regulation whereby genes in our cells talk to each other.”

Victor Ambros ‘75, PhD ‘79 and Gary Ruvkun have won the 2024 Nobel Prize in Physiology or Medicine for “their groundbreaking work on how genes behave,” reports Patrick Smith for NBC News. Ambros and Ruvkun, who worked as postdocs in the lab of Professor H. Robert Horvitz in the late 1980s, discovered how microRNA molecules play a key role in gene regulation. "The pair sought to explore how nerve cells and muscle cells, for example, have very different characteristics despite having the same genetic information," writes Smith.

Prof. Li-Huei Tsai, director of the Picower Institute, speaks with NPR host Jon Hamilton about her work identifying a protein called reelin that appears to protect brain cells from Alzheimer's. “Tsai says she and her team are now using artificial intelligence to help find a drug that can replicate what reelin does naturally,” says Hamilton. 

Prof. Ron Weiss co-founded Strand Therapeutics, a biotech company developing mRNA therapies, reports Emily Mullin for Wired. “The notion is that genetic circuits can really have significant impact on safety and efficacy,” says Weiss. “This begins to really open up the door for creating therapies whose sophistication can match the underlying complexity of biology.”

MIT researchers have “used an algorithm to sort through millions of genomes to find new, rare types of CRISPR systems that could eventually be adapted into genome-editing tools,” writes Sara Reardon for Nature. “We are just amazed at the diversity of CRISPR systems,” says Prof. Feng Zhang. “Doing this analysis kind of allows us to kill two birds with one stone: both study biology and also potentially find useful things.”

Researchers at MIT have developed a mobile vaccine printer capable of printing a vaccine onto a patch of microneedles that can be absorbed into the skin without injection, reports Sandra Tsing for NPR. “These printed vaccines could be used in areas that are unable to refrigerate traditional vaccines,” explains Tsing.

MIT researchers have discovered an RNA-guided DNA-cutting enzyme in eukaryotes, reports Science. “The researchers speculate that eukaryotic cells may have gained the newly identified editing genes from transposable elements—so-called jumping genes—they received from bacteria,” writes Science.

Prof. Richard Young and his colleagues have discovered that many transcription factors can bind RNA, reports Christie Wilcox for Science. "The team decided to investigate after scattered reports suggested that at least some transcription factors are capable of binding RNA even though they lack traditional RNA binding domains,” writes Wilcox. 

MIT researchers have identified a new biological editing system that could “potentially be even more precise than CRISPR gene editing,” reports Laura Baisas for Popular Science. The new system, based on a protein called Fanzor, is “the first programmable RNA-guided system discovered in eukaryotes,” Baisas notes.

Principal Research Scientist Ana Jaklenec speaks with CBC host Bob McDonald about her work developing a mobile vaccine printer. The device “can be very important in certain scenarios when you’re trying to bring the ability to vaccinate in areas that might not have the right infrastructure to make vaccines or even to administer vaccines,” says Jaklenec, “so I think the portability is key here.” 

Researchers at MIT have developed a new nanoparticle sensor that can detect cancerous proteins through a simple urine test. “The researchers designed the tests to be done on a strip of paper, similar to the at-home COVID tests everyone became familiar with during the pandemic,” writes Lambert. “They hope to make it as affordable and accessible to as many patients as possible.”

Researchers at MIT have developed a mobile printer that could create microneedle patches for mRNA vaccine delivery. “These "microneedle patches" offer a range of advantages over traditional jabs in the arm, including that they can be self-administered, are relatively painless, could be more palatable to the vaccine-hesitant and can be stored at room temperature for long periods of time,” writes Daniel Lawler for Agence France-Presse.

Research scientist Ana Jaklenec spoke with Jonathan Grinstein at Genetic Engineering & Biotechnology News about a new microneedle patch printer she and her colleagues have developed that may one day enable on-demand vaccine manufacturing. “The idea was that you could, in an emergency situation, deploy some of these printers and locally vaccinate the population to prevent the global spread of infection,” says Jaklenec.

Jake Becraft PhD ’19 and former postdoctoral associate Tasuku Kitada co-founded Strand Therapeutics, a biotech firm developing mRNA therapies for cancer, reports Ryan Cross for The Boston Globe. They created “a way to activate mRNA in the presence of particular microRNAs – a much more useful application for therapies,” writes Cross.